SAN DIEGO, Feb. 1 /PRNewswire/ -- Aurora Discovery today announced a purchase commitment from the National Institutes of Health's (NIH) Chemical Genomics Center (NCGC) for several low volume liquid-handling workstations. These workstations will be used in the development of chemical probe research at NCGC, which is being established as part of the Molecular Libraries Screening Centers Network initiative of the NIH Roadmap for Medical Research.
"Low volume, liquid-management fidelity is essential to our efforts to produce innovative chemical tools and libraries for use in biological research. Workstations play a key role in meeting that need," said NCGC Director Dr. Christopher Austin. The Flying Reagent Dispenser(TM) (FRD(TM)) is an automated, low volume bulk dispenser that significantly increases the productivity and performance of life science laboratories. The Picoliter Rapid Transfer Robot (PicoRAPTR(TM)) provides researchers with a non-contact alternative for low volume aspirate and dispense operations starting at 1nL in high-density microplates. The PicoRAPTR workstation is an ideal solution for rapid construction of broad dynamic range dose-response curves for concentration profiling applications in secondary screening.
"The FRD and PicoRAPTR workstations are becoming standard tools used by researchers in this new era of miniaturization solutions for discovery sciences. Aurora Discovery is pleased to be working with the scientists at the NCGC to help make their screening program run in an economic and scientifically efficient manner," said Peter Coassin, Aurora Discovery's President and CTO.
Aurora Discovery, Inc. is a leading provider of products and services that are used in early stage pharmaceutical research, particularly drug discovery and chemical genomics. Aurora Discovery's products shorten the time its takes to identify and evaluate new chemical entities and novel chemical structures against genomic targets in a biological or cell-based assay. Aurora Discovery's technologies accelerate drug discovery and help its pharmaceutical customers to select novel chemical entities quicker and ultimately, develop new medicines and therapies more rapidly and cost-effectively. Located in San Diego, California, the company provides high value solutions to the pharmaceutical research challenge through high-density microplate formats, precision non-contact dispensers for chemical compounds and biological reagents, multi-wavelength fluorescence detectors, and systems integration.
For more information, visit Aurora Discovery on its website at http://www.auroradiscovery.com/. For more information on the NIH Chemical Genomics Center, visit http://www.genome.gov/NCGC.
Aurora Discovery, Inc.
CONTACT: Chris Biagioli, Marketing Manager of Aurora Discovery, Inc.,+1-858-334-4508, email@example.com